,23 In particular, low-dose IL-2 (ld-IL-2) has been shown to be safe and to promote significant Treg expansion in healthy volunteers included in a phase I clinical trial24 as well as in phase I/II25–29 or II30,31 studies involving patients suffering from several autoimmune disorders. Here, IL2 is linked to autoimmune disease.